OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
68 hedge funds and large institutions have $65.4M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 29 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less funds holding
Funds holding: 85 → 68 (-17)
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
58% less capital invested
Capital invested by funds: $156M → $65.4M (-$90.6M)
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $222K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$15.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.19M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$776K |
| 5 |
Two Sigma Investments
New York
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.08M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.88M |
| 3 |
BlackRock
New York
|
-$3.79M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.41M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$809K |
OMED Hedge Fund Activity: Q2 2017 in Review
68 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2017, worth a combined $65.4M — down 58% from $156M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of OMED and 12 opened new positions — a net loss of 17 holders — while 26 trimmed existing stakes and 18 added.
The largest buyer was Primecap Management, adding an estimated $15.1M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.08M sold.
- 68 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2017, down from 85 in Q1 2017.
- Funds reported $65.4M of OncoMed Pharmaceuticals, Inc. stock for Q2 2017, down 58% quarter-over-quarter.
- 12 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2017 and 29 closed out, a net change of -17 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2017 was Primecap Management, an estimated $15.1M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2017 was Fidelity Investments, an estimated $9.08M sold.
Based on aggregated 13F filings for Q2 2017.